Frequency-shift based detection of BMS contrast agents using SSFP: potential for MRA.
A novel mechanism of MRI contrast enhancement, based on the detection by a balanced steady-state free precession (SSFP) sequence of the proton resonance frequency shift induced by bulk magnetic susceptibility (BMS) contrast agents, was investigated. The potential for this contrast mechanism to image blood vessels was explored. The relaxation time and the frequency shift effects of gadolinium- and dysprosium-DOTA on SSFP signal was first simulated and evaluated on a water phantom at 1.5 T. In vitro, a 5-mM concentration in contrast agent induced a 20-Hz frequency shift, leading to a signal increase of 92% for Dy-DOTA, and a 10-Hz frequency shift, leading to a signal increase of 58% for Gd-DOTA at the reference frequency, taking into account the nonlinear SSFP signal response on frequency offset. The concept was then evaluated in vivo on anesthetized rabbits. Low doses of dysprosium-DOTA were injected in their vascular system, and imaging was performed at the level of neck vessels. Following a bolus injection, mean signal changes of 31%, 20% and 14% were observed in the carotid arteries, the vertebral veins and the jugular veins, respectively. The bolus peak times in arteries and veins were consistent with the rabbit vascular circulation. This frequency-shift based contrast mechanism presents interesting potential for contrast-enhanced MR angiography (CE-MRA) compared to usual relaxation-based contrast, but further investigations on reproducibility will be necessary.
Dubois
Jessica
J
Service Hospitalier Frederic Joliot, Commissariat a l'Energie Atomique, 91 401 Orsay Cedex, France.
Lethimonnier
Franck
F
Vaufrey
Francoise
F
Robert
Philippe
P
Le Bihan
Denis
D
D000818:Animals; D003198:Computer Simulation; D003287:Contrast Media / Q000008:administration & dosage; D005240:Feasibility Studies; D006571:Heterocyclic Compounds / Q000008:administration & dosage; D007089:Image Enhancement / Q000379:methods*; D018810:Magnetic Resonance Angiography / Q000379:methods*; D009333:Neck / Q000098:blood supply; D009942:Organometallic Compounds / Q000008:administration & dosage; D019047:Phantoms, Imaging; D011817:Rabbits
D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C116672:dysprosium-DOTA-PAMAM; C050823:gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate